Webinars and Presentations

Webinars & Presentations

Applications

Virus-like Particles
Cell Based Assays
Cell Therapy
CRISPR/Gene Editing
Gene Editing
Protein Production

Cell Types

Cancer Cell Lines
CHO
Dendritic Cells
HEK293
HSPCs
Insect Cell Lines (S2/Sf9/Sf21)
ion channels
iPSCs
NK Cells
NPCs/NSCs
PBMCs
T Cells

Cover slide of presentation of 2024 European Society of Gene and Cell Therapy Congress - Efficient, scalable manufacturing of virus-like particles for the delivery of gene editor ribonucleoproteins using a cGMP-compliant electroporation platform

Virus-like Particles

CRISPR/Gene Editing

Gene Editing

HEK293

Efficient, Scalable Manufacturing of Virus-like Particles for the Delivery of Gene Editor Ribonucleoproteins Using a cGMP-compliant Electroporation Platform

Our MaxCyte scientist, Isabel Daher, presents her poster from the 2024 European Society of Gene and Cell Therapy annual meeting. MaxCyte’s electroporation platform efficiently produces high-potency VLPs, outperforms chemical transfection, and is scalable for clinical and commercial manufacturing.

Virus-like Particles

CRISPR/Gene Editing

Gene Editing

HEK293

Poster: Efficient Scalable Manufacturing of Virus-Like Particles for the Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP-Compliant Electroporation Platform

Our MaxCyte scientist, Isabel Daher, presents her poster from the 2024 American Society of Gene and Cell Therapy annual meeting. In this study, we utilized the MaxCyte ExPERT GTx, a cGMP-compliant electroporation instrument, to manufacture virus-like particles—packaged with CRISPR-Cas9 RNPs for genome editing in target cells—in adherent and suspension HEK293 cells.

CRISPR/Gene Editing

Gene Editing

Gene Therapy

T Cells

2024 ASGCT Presentation – Streamlining the CRISPR Editing Process in an eTIL Cell Therapy

KSQ Therapeutics shares their presentation on developing a scalable cGMP process for their engineered tumor-infiltrating lymphocyte (eTIL™) cell therapy.

Cell Therapy

Gene Editing

Primary Cells

NK Cells

Poster: Non-Viral Cell Engineering of Peripheral Blood Natural Killer Cells Using a GMP-Compliant, Scalable Electroporation Platform

Our MaxCyte scientist, Lauren Unsworth, presents her poster from the 2024 American Society of Gene and Cell Therapy annual meeting. In this study, we optimized conditions for electroporating primary NK cells with the GMP-compliant MaxCyte ExPERT GTx electroporation platform, with specific focus on maximizing cell viability, cell recovery, transfection efficiency, cell expansion and functionality.

Cell Based Assays

CRISPR/Gene Editing

Gene Editing

iPSCs

Webinar: Unlocking the Potential of Electroporation for Studying Ion Channel-Related Disorders and iPSCs

In this GEN webinar, Dr. Alfred George discusses an electroporation approach that addresses efficiency challenges and engineers target cells at unprecedented scale. He also discusses MaxCyte electroporation and how it was used to express human ion channel variants in cultured mammalian cells to enable high throughput automated patch clamp recording. The MaxCyte STx enabled functional evaluation of ion channel variants without requiring stable cell line creation. You’ll learn how to use electroporation to create or correct mutations in induced pluripotent stem cells (iPSCs) for modeling human genetic diseases and providing proof of concept for gene therapy.

CRISPR/Gene Editing

Gene Editing

Primary Cells

TCR/CAR T

CAR T

Seminar: Non-viral Cell Engineering Advantages and Applications with Stanford University, Touchlight and MaxCyte

Key case studies are presented by Dr. Hyatt Want at Stanford University (Crystal Mackall & Steve Feldman Labs), Dr. Elena Stoyanova at Touchlight Genetics, and Dr. Marianna Romito at MaxCyte. Each presenter shares data on how to increase engineering efficiency in primary and stem cells, all while maintaining high cell viability and recovery for applications in gene editing and autologous/allogeneic cell therapy.

Cell Therapy

CAR T

T Cells

Seminar: University of Pennsylvania – High Efficiency Cell Engineering

The High Efficiency Cell Engineering Seminar was hosted at the University of Pennsylvania on Friday, October 27, 2023, with our special guest, Nils Wellhausen, who is co-mentored by Drs. Carl June and Saar Gill, recently published a novel therapeutic strategy for the treatment of most blood cancers. This presentation showcased the development of fratricide-resistant, base-edited CD45-targeting CAR T cells and CD45 epitope-edited hematopoietic stem cells. This approach paves the way forward for a universal blood cancer immune therapy.

Cell Therapy

CRISPR/Gene Editing

Gene Therapy

TCR/CAR T

CHO

iPSCs

T Cells

Seminar: Non-viral Cell Engineering – Catamaran, CCRM and MaxCyte

Register to delve into the future of cellular engineering by viewing the on demand seminar on Non-viral Cell Engineering from Catamaran, CCRM and MaxCyte. Our special guest, Catamaran Bio, will showcase their innovative, transposon-based approach to CAR-NK cell engineering and demonstrate how MaxCyte and CCRM scientists helped enable their clinical development and advancement.

Cell Therapy

Protein Production

Vaccines

NK Cells

T Cells

Webinar: CHOp your protein production timelines

Learn how to drive your biologics development forward by leveraging MaxCyte^® Flow Electroporation^® technology. This flexible, scalable technology enables alternative strategies for the rapid development of high-yielding stable cell lines and can deliver gram-scale transient protein production within two weeks. Hosted with Labroots on September 12, 2023.

Cell Therapy

CRISPR/Gene Editing

Gene Editing

Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Watch the video to learn how choosing a clinically validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing.